Compare CRNX & BKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | BKD |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | 33000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | BKD |
|---|---|---|
| Price | $42.21 | $15.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $76.75 | $15.10 |
| AVG Volume (30 Days) | 1.3M | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | N/A |
| Revenue Next Year | $184.67 | $4.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $7.00 |
| 52 Week High | $57.99 | $17.09 |
| Indicator | CRNX | BKD |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 72.40 |
| Support Level | $38.68 | $13.08 |
| Resistance Level | $44.89 | $17.09 |
| Average True Range (ATR) | 1.71 | 0.59 |
| MACD | 0.74 | 0.26 |
| Stochastic Oscillator | 97.89 | 87.48 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.